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Summary This study has been designed to verify the specific toxicity of saporin, a type I ribosome-
inactivating protein (RIP), with the same activity as ricin A chain, targeted by a bispecific monoclonal
antibody (bimAb) recognising both the CD25 antigen and the RIP.
The CD25 antigen is expressed by lymphoid populations upon activation and by leukaemias and lym-
phomas with an activated membrane phenotype (Hodgkin's lymphoma, anaplastic large cell lymphoma, adult
T cell leukaemia). The bimAb-saporin mixture was tested on CD25 + targets at different bimAb and saporin
concentrations. Saporin, in the presence of a bimAb concentration of lo-9 M, inhibited protein synthesis by
CD25 + neoplastic lymphocytes (L540 and MT2 cell lines) with ICms (concentrations giving 50% of inhibi-
tion) ranging from 8 x 10-2 M to 3 x 10-" M. The saporin-bimAb mixture was also effective in blocking the
phytohaemagglutinin-driven proliferation of normal lymphocytes, whereas it displayed the same level of
toxicity exerted by saporin alone on an irrelevant CD25-negative cell line (EBV-infected B lymphoblastoid cell
line). From these results it is possible to envisage a clinical use of this bimAb as a cytotoxic agent for CD25 +
leukaemias and lymphomas, as well as an immunosuppressive agent for severe immune disorders such as
graft-vs-host disease (GVHD) and transplanted organ rejection.
The use of monoclonal antibodies to kill selected cell popula-
tions has come under intense investigation in recent years.
One of the possible approaches is the chemical linkage of a
toxic moiety to a monoclonal antibody to produce 'immuno-
toxins' recognising a molecule restricted to the unwanted cell
population (reviewed in Frankel, 1988). Ricin A chain is the
most common toxic moiety used so far, but several single-
chain ribosome-inactivating proteins (type 1 RIPs) are also
available, which are easier and safer to purify, and can be
used to prepare potent immunotoxins (Stirpe et al., 1992).
An alternative approach to conventional immunotoxins, to
selectively deliver toxic moieties to neoplastic cell popula-
tions, is the use of bispecific monoclonal antibodies (bimAbs)
(Glennie et al., 1988; Laky et al., 1987), which simultaneously
recognise a toxin and a tumour-associated antigen.
Lymphocyte activation antigens represent appropriate
targets for antibody-driven drug delivery in haematopoietic
malignancies (Engert et al., 1990; Tazzari et al., 1992a,b). In
fact some of them are not expressed on vital tissues (Herve'
et al., 1990; Falini et al., 1992), such as liver, kidney, central
nervous system, heart, vessels and lung. Thus it has been
possible to devise in vitro and in vivo models of drug
targeting by utilising monoclonal antibodies recognising the
CD25 and the CD30 lymphoid activation antigens (Engert et
al., 1990; Tazzari et al., 1992a,b), expressed on well-defined
neoplastic lymphoid populations, such as Hodgkin's lym-
phomas, anaplastic large cell lymphomas (ALCL), and adult
T-cell leukaemia (ATL).
To date bimAbs (Milstein & Cuello, 1984) have been
mainly generated in order to target cytotoxic effectors to
tumours (Staerz & Bevan, 1986; Lanzavecchia & Scheidegger,
1987; Ferrini et al., 1989; Ferrini et al., 1991). A small series
of bimAb have also been obtained to target RIPs to
haematological neoplasias (Glennie et al., 1988). Good pre-
clinical in vitro and in vivo results were described, and clinical
trials are also ongoing (Bonardi et al., 1992).
In this study we described a bimAb, secreted by a hybrid
hybridoma, which is capable of recognising the CD25
molecule and saporin. This bimAb is able to specifically
enhance the toxicity of free saporin against CD25 + targets.
In fact, in the presence of saporin, the bimAb is able to
induce killing of Hodgkin's-derived and ATL-derived CD25 +
cell lines, as well as to inhibit phytohaemagglutinin (PHA)-
driven proliferation of normal lymphocytes; on the contrary
the same bimAb is ineffective on a lymphoblastoid cell line
(LCL) lacking CD25 surface expression.
Materials and methods
Ribosome-inactivating proteins
Saporin, PAP-S, PAP-L, momordin and gelonin were
prepared as described by Barbieri et al. (1987). Ricin A chain
was purchased from Sigma.
Production ofanti-saporin hybridoma and ofenzyme-deficient
hybridoma mutants
To produce anti-saporin mAbs, 6-week-old Balb/c mice were
immunised by s.c. injections of 1 yg of saporin in complete
Freund's adjuvant. After 2 weeks, mice were further
immunised three times with the same amount of saporin in
incomplete adjuvant at weekly intervals. After 10 days mice
received a booster injection of 1 jg of saporin, followed by
splenectomy 3 days later. Immune splenocytes were fused
with P3Ul myeloma cells. Hybrid cells were selected by
culture in HAT medium 18 h after the fusion. Screening of
the hybridoma supernatants was performed by a conven-
tional ELISA assay using saporin-coated microtiter plates
and a peroxidase-conjugated rabbit anti-mouse Ig as detec-
tion system (Perry & Kierkegaard). Three hybridomas,
named CY12, CY56 and CY62 were selected according to
this screening and were repeatedly subcloned by limiting
dilution. All anti-saporin mAbs belonged to the IgGI isotype
and displayed a strong reactivity in ELISA assays with
saporin without cross-reactivity with other RIPs. Culture
medium for hybrids was D-MEM (Seromed) supplemented
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with 10% FCS (Seromed) and 2 mM L-glutamine (Flow).
The MAR93 (IgGI) hybridoma produces an anti-CD25
mAb (Lopez Botet et al., 1986). Hypoxanthine-guanine phos-
phoribosyltransferase (HGPRT)-deficient mutants of the
CY12.14 hybridoma were selected by culture in the presence
of increasing amounts of 8-azaguanine (1 to 50 jgml-')
(Sigma, St. Louis, MO). Hybrid mutants were cloned by
limiting dilution and tested for HAT sensitivity and antibody
production.
Cellfusion and screening ofhybrid hybridomas
The HGPRT-CY12.14 clone was fused with an iodoacet-
amide-inactivated MAR93 hybridoma cells at a 1: 1 ratio
using a standard polyethylene glycol fusion protocol (Clark
& Waldman, 1987; Suresh et al., 1986). Hybrid hybridomas
were selected by culture in HAT medium. Culture super-
natants were tested for their ability to react with saporin in
ELISA assay and with CD25 + cells in an indirect
immunofluorescence assay. Double-positive cultures were
immediately subcloned by limiting dilution.
BimAbpurification
Anti-saporin/anti-CD25 bimAb was purified from ascitic
fluid by affinity chromatography on saporin coupled with
Sepharose (Pharmacia). CnBr-activated sepharose (4 ml) was
coupled with purified saporin (10 mg) previously dialysed
against coupling buffer (NaHCO3 0.1 M pH 8.3, NaCl 0.5 M).
Ascites was dialysed against 1O mM Tris (pH 7.5) and then
incubated with saporin-sepharose for 1 h at 4°C. The elution
of the bound material was performed by applying 100 mM
glycine pH 4 and 100 mM glycine pH 2.5. The eluted frac-
tions were collected in tubes containing an appropriate
volume of 1 M Tris pH 8.0 to neutralise the pH. Reactivity of
the purified bimAb with CD25 + targets was further checked
by immunofluorescence, as described below.
Cell lines
Two different CD25 + cell lines have been used throughout
the study: L540 (a kind gift of Dr A. Engert, Immuntoxin
Labor, Medizinische Klinik, Kohln, Germany), derived from
the lymph node of a Hodgkin's lymphoma patient (Engert et
al., 1992; ATL-derived MT2 (Miyoshi et al., 1981) (a kind
gift of Prof. 0. Varnier, Institute of Microbiology, University
of Genova, Italy), derived from HTLV-I-infected cells. A
conventional Epstein Barr Virus (EBV)-transformed, CD25-
negative B LCL, was used as an irrelevant target. All cells
were maintained in RPMI 1640 medium containing 10%
foetal bovine serum (FBS) glutamine and antibiotics (all
reagents were from Seromed). Cells were used for assays
during the logarythmic phase of growth. Viability was
checked by trypan blue dye exclusion.
Immunofluorescence staining
The reactivity ofbimAb was checked by indirect immunofluor-
escence on CD25-positive (L540, MT-2 and PHA-activated
lymphoblasts) and CD25-negative cells (EBV-transformed B
cell lines). Briefly, cells from the above cell lines were
incubated with the bimAb anti-CD25, and with the two
parental mAbs (anti CD25, MAR93, and anti-saporin,
Cyl2.14) for 30 min at 4°C. After two washes with cold
phosphate buffered saline (Gibco) containing 2% of FBS
(PBS-FBS) the cells were incubated for 30 min at 4°C with
5 glI of FITC-conjugated sheep anti-mouse-IgG immuno-
globulins. After two washes with PBS-FBS, the samples were
analysed by an EPICS cytofluorimeter. Appropriate Ig mat-
ched controls were run for each sample.
Protein synthesis inhibition
Cells (2 x 104) were seeded in 96 well U-bottomed plates in a
volume of 100;1l of complete RPMI 1640 medium. Saporin
and bimAb were added to a final volume of 200 tl. Different
concentrations of bimAb (from 10-' to 10-13 M) were tested,
in the presence of saporin (from 10-8 to 10-13 M) in order to
titrate both reagents. Appropriate control samples were run
with cells alone, saporin alone, parental mAbs alone, or
saporin plus parental mAbs, mixed together. After 24 h of
incubation 2 iCi of 3H-Leucine (Amersham) were added to
each well. After additional 18 h the cells were harvested onto
glass fiber filters by a cell harvester (ICN-Flow), and the
radioactivity was evaluated by a P-computer (Packard), as
already described (Tazzari et al., 1992a,b). Each experiment
was run in triplicate. Mean values of five different
experiments are expressed as percentage of control values.
s.d. <15%.
Inhibition of3H-thymidine uptake by PHA-stimulated
lymphocytes
Normal T lymphocytes, upon activation, express the CD25
antigen. Thus we assayed the same combinations of saporin,
bimAb, and parental mAbs as described above, on PHA-
activated peripheral blood lymphocytes. Briefly, heparinised
peripheral blood was obtained by venesection from five heal-
thy volunteers, gradient-separated on a Ficoll-Hypaque
cushion, counted and adjusted to a concentration of 5 x 105
cells ml-' in complete RPMI 1640 medium containing 10%
AB serum (Gibco). One hundred microliters of cell suspen-
sion (5 x 104 cells) were then seeded in 96-well flat-bottomed
plates (Falcon) in the presence of 5 yg ml-' of PHA (Sigma);
100ILI of different dilutions of saporin + bimAb, saporin
alone, bimAb alone or appropriate mixtures of parental
antibodies and saporin were added as described in the
previous paragraph. After 48 h of incubation, 3H-thymidine
(Amersham) (0.5lLCi per well) was added. After additional
24 h of incubation, cells were harvested onto glass fiber
diskettes and processed as described above.
Each experiment was run in triplicate. Mean values of five
different experiments are expressed as percentage of control
values. s.d.<15%.
Cell killing efficiency
To evaluate the actual killing capacity, 2 x 105 cells L540
cells were seeded in 24 wells plate in a final volume of 1 ml of
complete RPMI 1640 medium, and incubated with different
combinations of bimAb and saporin (see Table I). Controls
with saporin alone or bimAb alone were run. After 72 h of
incubation at 37°C cell viability was evaluated using a stan-
dard trypan blue exclusion assay. A 72 h period of culture
was selected for this assay on the basis of time course
experiments, which indicated that this period of culture
induced an optimal cell killing effect. Results were expressed
as % of viable cells (mean values of three experiments run in
triplicate, with s.d. < 15%).
Results
Characterisation ofanti-saporin mAbs
Three hybridomas secreting anti-saporin mAbs were pro-
duced by the fusion of immune mouse splenocytes with the
Table I Cytotoxic effect of bimAb in the presence of saporin on
CD25 + tumour cells
BimAb (M) No
10-8 i0-9 1010 addition
Saporin (M)
10-8 2%a 11% 27% 67%
-9 9% 2% 65% 98%
10-10 69% 72% 78% 95%
No addition 98% 99% 97% 95%
aData are expressed as % of viable L540 cells, evaluated by trypan
blue exclusion.1250 P.L. TAZZARI et al.
P3U1 myeloma. All hybrids secreted IgGI mAbs which
reacted with saporin in an ELISA assay, while they failed to
react with other RIPs - momordin, gelonin, ricin-A chain,
PAP-S and PAP-L. These results were confirmed by western
blot analysis which showed that mAbs only reacted with the
30 kD saporin molecule (data not shown).
We next investigated whether the three mAbs could
interfere with the ribosome-inactivating activity of saporin in
a cell-free protein synthesis inhibition assay (Stirpe et al.,
1983; Bolognesi et al., 1992). Two of them (CY56 and CY62)
displayed >80% of inhibition of the ribosome-inactivating
activity, while the third (CY12.14) had virtually no inhibitory
activity. To exclude the possibility ofinhibitory effects on the
ribosome-inactivating activity of saporin, the CY12.14
hybridoma was used for bimAb production.
Selection ofa hybrid hybridoma producing anti-saporinl
anti-CD25 bimAbs
To produce hybrid hybridomas secreting bimAbs a HGPRT-
deficient CY12.14 anti-saporin hybridoma clone was fused
with chemically inactivated cells of the anti-CD25 MAR93
hybridoma. After selection in HAT medium, hybrid hybrid-
oma supernatants were screened for their ability to react
simultaneously with saporin in ELISA and with CD25 +
cells in immunofluorescence assays. Hybrids were repeatedly
subcloned by limiting dilution and several subclones with
double reactivity were selected. The supernatant of selected
clones was then analysed for its ability to enhance saporin
toxicity against CD25 + L540 target cells in a 3H-leucine
uptake assay. The TC37 subclone displayed the highest
activity in this assay, while the supernatant of other hybrid
hybridoma subclones had less or no effect (data not shown).
This finding may be related to either chromosomal ins-
tability, leading to the loss of Ig genes, or to the secretion of
different amounts of correctly assembled bispecific antibody
compared to other possible combinations of secreted
antibodies (Milstein & Cuello, 1984). BimAb was then
purified from TC37 hybrid hybridoma ascites by affinity
chromatography on a saporin-Sepharose column and utilised
for further studies.
BimAb reactivity
The CD25 + L540 and MT2 cell lines strongly reacted with
the bimAb or with the parental anti-CD25 mAb as assayed
by immunofluorescence, whereas they did not react with the
anti-saporin CY12.14 mAb (Figure 1). In addition the bimAb
reacted with 20-30% of 48 h PHA-stimulated normal lym-
phocytes, but not with a CD25-negative (EBV)-transformed
B LCL (data not shown). Thus the bimAb recognising both
CD25 antigen and saporin maintains the capability of selec-
tively recognising CD25 + cells.
Effect ofbimAb-saporin combinations onprotein synthesis
inhibition
Titration experiments using serial concentrations of both
bimAb and saporin were performed with the L540 and MT2
CD25 + cell lines. As shown in Figure 2b protein synthesis
by L540 cell line was inhibited by saporin with an ICs
(concentrations giving 50% inhibition in comparison to con-
trol values) of 8 x 10-12M, in the presence of I0-9M of
bimAb, which was the optimal concentration for enhancing
saporin toxicity. In the presence of 10-8 M of bimAb saporin
had an IC50 of 5 x 10- M, suggesting that the bimAb was in
excess in comparison to the capacity of cell binding sites,
thus preventing saporin internalisation. An IC50 of 2.5 x
10` M (as saporin) was obtained in the presence of a con-
centration of 101 M of bimAb. BimAb concentrations of
10-"1 M, 10-12 M and I0-' M were effective with an IC50 of
3 x 10-'° M, 7 X 10-'0 M and 9 x 10`0 M, respectively. The
bimAb alone did not inhibit protein synthesis. Saporin alone
had an ICR, of 4 x 10-9M (Figure 2a), which was not
enhanced in the presence of the parental antibody against
saporin (CY12.14), and was virtually unchanged by the mix-
ture of the two parental mAbs (anti-CD25 and anti-saporin
mAbs) (Figure 2a).
Similar results were obtained using the ATL-derived MT2
cell line. In particular maximum inhibition of protein syn-
thesis was obtained at concentrations of 10-9 M and 10-10 M
of bimAb (saporin IC50s were 3 x 101-1 M and 1.3 x 10-10 M
respectively, Figure 3b). At a bimAb concentration of 10-8 M
MT2 cell line
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Figure 1 Cytofluorimetric analysis of anti-saporin/anti CD25 bimAb reactivity on the CD25 + MT2 cell line by indirect
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Figure 2 Inhibition of protein synthesis by the L540 target cells
treated with different bimAb/saporin combinations. Experiments
performed as described in Materials and methods section.
s.d. < 15%. a, as experimental controls, L540 cells were treated
with: saporin alone -A-, anti-CD25 mAb alone -+-, anti-
saporin mAb alone -O-, bimAb alone -0-, anti-saporin
mAb + saporin -x -, anti CD25 mAb + saporin -A-, anti-
saporin mAb+ anti-CD25 mAb+saporin -M-. b, L540 cells
were treated with different concentrations of bimAb in the
presence of serial dilutions of saporin (I0 8 to 10-'3 M). BimAb
concentrations: 10-1 M-+-; 10-9M -0-; 10-'OM--; 10-" M
-X-; 10-'2M -*-; l0-'3M -0-.
a lower degree of inhibition was observed (ICm4 of
1.5 x 10-` M as saporin), as already observed for the L540
cell line. Concentrations of bimAb ranging from 10-II M to
I0-'3 M gave saporin IC50s ranging from 8 x 1010 M to
9 x 10-1 M. Different mixtures of parental antibodies and
saporin did not specifically affect protein synthesis by MT2
cells (Figure 3a).
A CD25-negative EBV-transformed LCL was used as an
irrelevant target in a 3H-leucine uptake assay. No enhance-
ment of saporin specific toxicity was obtained by testing all
the combinations of bimAb and saporin, as described above
(data not shown).
Cytotoxic effects ofbimAb-saporin combination
To verify that cells were indeed killed by bimAb-saporin
combination, we evaluated cell viability after 48 h of incuba-
tion. Trypan blue-dye exclusion assay demonstrated that
L540 cells were efficiently killed (only 2-11% of viable cells)
at concentrations of bimAb ranging from 10-8 M to 10-9 M
in the presence of saporin concentrations in the same range.
Under the same conditions saporin alone induced only a
partial loss of viability at a concentration of 10-8 M (67% of
viable cells) (Table I).
Inhibition of3H-thymidine incorporation on PHA-stimulated
lymphocytes
Since the CD25 antigen is expressed on normal T-
lymphocytes upon activation, we investigated whether com-
binations of bimAb and saporin were effective in blocking
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Figure 3 Inhibition of protein synthesis by the MT2 target cells
treated with different bimAb/saporin combinations. Experiments
performed as described in Materials and methods section.
s.d. <15%. a, as experimental controls, MT2 cells were treated
with: saporin alone -A-, anti-CD25 mAb alone -+-, anti-
saporin mAb alone -0-, bimAb alone -0-, anti-saporin
mAb + saporin -x-, anti CD25 mAb + saporin -A-, anti-
saporin mAb+anti-CD25 mAb+ saporin -U-. b, MT2 cells
were treated with different concentrations of bimAb in the
presence of serial dilutions of saporin (10-8 to 1i-'3 M). BimAb
concentrations: lo0- M -+-; 10-9 M -0-; 10-10 M -A-; 10 M
-X-; 10-12 M -*-; 10-'3 M -0-.
3H-thymidine incorporation in PHA-stimulated lymphocytes.
Our experiments demonstrate that, in the presence of bimAb
ranging from l0-' M to 10-' M, saporin had IC"s of
10-" M, 3.8 x 10-
" M and 6 x 10-" M respectively (Figure
4b). Lower concentrations of bimAb (from 10-11 M to
10-'3 M) resulted in IC50s of 2 x 10-'° M, 5.5 X 10-'° M, and
2 x 10-9 M respectively (Figure 4b). In the presence of a
mixture of both parental mAbs, saporin showed an IC50 of
4 x 10-9 M. Parental mAbs had no toxicity, while saporin
alone had an IC50 of 10-1 M (Figure 4a).
Altogether, these results indicate that the anti-CD25/anti-
saporin bimAb is able to efficiently target the toxic activity of
saporin against both normal and neoplastic CD25 + lym-
phoid cells.
Discussion
In this study we described a bimAb recognising both the
CD25 antigen and saporin, one of the most powerful RIPs
type 1 (Stirpe et al., 1983; Thorpe et al., 1985; Stirpe et al.,
1992; Bolognesi et al., 1992). The bimAb enhanced saporin
toxicity against both normal and neoplastic CD25 + lym-
phoid cells lowering saporin IC50s to about 10-"1 M in the
presence of 10-9 M and 10-10 M bimAb. Irrelevant CD25-
negative target cells were unaffected, thus confirming the
specificity of the bimAb targeting activity.
These data were obtained by the evaluation of the
inhibitory effect on protein and DNA synthesis. Indeed the
bimAb-toxin mixture had cytotoxic effects as demonstrated
by a loss of cell viability, even though the latter assay shows
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Figure 4 Inhibition of DNA synthesis in PHA-stimulated lym-
phocytes treated with different combinations of bimAb and
saporin. Experiments performed as described in Materials and
methods section. s.d. <15%. a, as experimental controls, PHA-
stimulated lymphocytes were treated with: saporin alone -+-,
anti-CD25 mAb alone -A-, anti-saporin mAb alone -A-,
bimAb alone -0-, anti-saporin mAb + saporin -0-, anti CD25
mAb + saporin -x-, anti-saporin mAb + anti-CD25 mAb +-
saporin -A-. b, PHA-stimulated lymphocytes were treated with
different concentrations of bimAb in the presence of serial dilu-
tions of saporin (10-8 to 10`-1 M). BimAb concentrations:
100 M -+-; 10-9 M -0-; 10'lo M -A-; 10-11 M -X-; 10-12 M
-U-; 10 I3'M -0-.
usually a lower degree of sensitivity (Tazzari et al., 1992a,b).
The ability of the bimAb to enhance saporin toxicity was
strictly dependent on its double specificity, since parental
(anti-saporin or anti-CD25) mAbs, either alone or in com-
bination, were uneffective.
It should be pointed out that the double specificity of the
bimAb was demonstrated by its ability to recognise CD25 +
target cells after the affinity chromatography purification on
saporin-Sepharose. This purification procedure allowed the
removal of antibody species not reacting with saporin (such
as parental anti-CD25 mAb) secreted by the hybrid hybri-
doma, while parental anti-saporin mAb co-eluted together
with bimAb. Therefore, the complete removal of other anti-
body species (such as parental anti-saporin mAb) from bimAb
preparations, by the use of additional purification steps, may
result in an enhancement of bimAb targeting activity.
One of the basic conditions for a possible in vivo targeting
is the reactivity of the reagent of choice with a restricted cell
population, excluding vital tissues. The CD25 antigen could
be an optimal choice, since in normal healthy individuals it is
expressed only on small fractions of activated B- and T-
lymphocytes (Herve' et al., 1990). The CD25 molecule
represents the a-chain of the interleukin-2 (IL-2) receptor
complex. This chain, together with the IL-2 receptor P chain,
forms the high affinity IL2-receptor which is expressed on
both T- and B-lymphocytes after activation (Dukovich et al.,
1987; Robb et al., 1987). Thus CD25 plays a key role in the
control of IL-2-driven T and B lymphocyte proliferation and
in the clonal expansion of antigen-specific lymphocytes.
Therefore the possible clinical applications of anti-CD25
mAbs may be the targeting of CD25 + lymphoid cell
tumours, or of CD25 + normal cells in severe immune
disorders such as GVHD and transplanted organ rejection.
In a previous study we described an immunotoxin obtained
by conventional chemical linking of a CD25 mAb and
saporin, with a very high specific in vitro activity (IC50 of
approximately 10-12 M as linked saporin), which was
designed for the therapy of steroid-resistant GVHD, as well
as of CD25 + lymphomas (Tazzari et al., 1992b). Moreover
our group recently reported in vitro and in vivo results
obtained in CD30 + lymphoid neoplasias with an immuno-
toxin containing an anti-CD30 mAb (Ber-H2) chemically
linked to saporin (Tazzari et al., 1992a; Falini et al., 1992).
Encouraging clinical results confirmed the high activity of
saporin-containing conjugates demonstrated in the in vitro
assays (Thorpe et al., 1985; Siena et al., 1988; Tazzari et al.,
1988). The major limitations were represented by (i) the
higher toxicity of linked saporin in comparison to free
saporin (LD50 in mice 1 mg kg-' vs 1Omg kg' (Thorpe et
al., 1985; Marcucci et al., 1989)) and (ii) the formation of
anti-saporin and anti-mouse IgG antibodies, with increased
risk of anaphylaxis due to a possible enhanced immuno-
genicity of linked saporin (Falini et al., 1992; F. Stirpe,
personal observations). Thus the possible advantages of the
in vivo use of bispecific antibodies recognising both the
relevant target and saporin are (i) the possibility of in vivo
targeting with higher doses of mAb and saporin; (ii) a lower
probability of anaphylaxis after repeated administrations and
(iii) to avoid the partial and in some cases (gelonin) almost
total inactivation of RIPs which may occur during the
chemical conjugation to antibodies (Bolognesi et al., 1992).
Immunotoxins consisting of mAbs and toxic moieties may
provide efficient tools to reduce the toxicities of conventional
chemotherapeutic and immunosuppressive protocols. The
bimAb herein described could provide the basis for a clinical
trial, devised to effectively target and kill CD25 + unwanted
populations, both normal and of neoplastic origin. In this
context bispecific antibodies recognising saporin and B-cell
antigens have recently been reported and were used in a
clinical trial in patients with CD22 + low grade lymphomas,
with encouraging clinical results (Bonardi et al., 1992).
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